SupplySide Supplement Journal Honored as Neal Awards Finalist
PHOENIX, AZ / ACCESS Newswire / March 26, 2025 / Informa Market's SupplySide portfolio proudly announces industry publication SupplySide Supplement Journal has been named a finalist in the 71st annual edition of the Software Information Industry Association's (SIIA) Jesse H. Neal Awards, the most prestigious awards for business journalism and content creation. The Neal Awards honor the brightest, most tenacious and innovative journalists, content creators and designers for outstanding passion and exceptional work.
SupplySide Supplement Journal is a business-to-business media brand that connects ingredient buyers and suppliers in the health and nutrition market. It offers daily news on vitamins, dietary supplements, nutrition trends and ingredient science, while providing insights on business, science and regulatory issues affecting the supplement industry. The journal's audience comprises professionals across the consumer-packaged goods supply chain, including those involved in research and development (R&D), formulation, marketing and executive management. Readers rely on the journal for trustworthy information on raw material ingredients, nutritional science, ingredient discoveries, intellectual property developments, regulatory updates and competitive insights. This comprehensive resource serves as a vital link between various stakeholders in the health and nutrition marketplace, offering timely and relevant information to support decision-making and industry advancement.
Selected as a finalist in the category 'Best Government, Legislative and Regulatory Coverage,' the nomination recognizes the Journal's groundbreaking investigative coverage, " A Yearlong Battle Against Drug-Spiked Supplements." This in-depth article, spearheaded by SupplySide associate editorial director Josh Long, exposed the ongoing sale of mislabeled, drug-products by a distributor, despite receiving a warning letter from the U.S. Food and Drug Administration (FDA). This nomination underscores SupplySide Supplement Journal's commitment to rigorous reporting of regulatory and policy issues in the supplement industry.
Through independent testing and requests through the Freedom of Information Act, which provides the public the right to request access to records from federal agencies like FDA, the SupplySide editorial team divulged that the distributor was continuing to sell a product (AK Forte) containing pharmaceutical-grade doses of an anti-inflammatory drug first tested by FDA. It was not until the article was published in May 2024 that the distributor stopped marketing AK Forte, more than a year following an FDA public advisory and 11 months after receiving an FDA warning letter.
Photo courtesy of the FDA
'As reporters, our mission is to uncover and communicate news that profoundly impacts both the industry and consumers. We delve into compelling narratives on critical topics, including regulation and legislation,' states Sandy Almendarez, Vice President of Content for SupplySide. 'Our commitment is twofold, to keep the industry well-informed and safe, and to unearth crucial stories that demand attention. It is a privilege to be recognized for our editorial team's meticulous investigation and thorough research. Our work sheds light on issues with far-reaching implications, driving meaningful conversations and change in the industry.'
Finalists for the awards program are chosen by a panel of judges based on the highest-scoring entries in their respective categories, celebrating the best in B2B journalism across a range of disciplines from investigative reporting to design and overall editorial impact. The winners will be announced on May 16, 2025, at an awards luncheon at The Yale Club in New York City.
About SupplySide
Informa Markets' SupplySide portfolio, a subsidiary of Informa plc (LON:INF), is the leading B2B event producer, publisher and digital media business for the world's dietary supplement, food and beverage, pet health and personal care industries. Our events, SupplySide Global and SupplySide Connect New Jersey and multi-time FOLIO's: Eddie winning and nominated publications SupplySide Supplement Journal and SupplySide Food & Beverage Journal bring together thousands of suppliers and buyers globally to explore and learn about the latest products, services, research, regulatory changes and more in the health and nutrition industry for nearly 3 decades. The SupplySide portfolio is organized by Informa, the world's leading exhibition organizer that brings a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com.
Informa Markets, a subsidiary of Informa plc (LON:INF), creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio comprises more than 550 international B2B events and brands in markets including Engineering, Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world's leading exhibitions organizer, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, visit www.informamarkets.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
6 hours ago
- Business Insider
Sarepta says eight-year-old death deemed unrelated to Elevidys
Sarepta (SRPT) said in a statement Friday night: 'Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy patient who had received Elevidys gene therapy. The death of this patient was deemed unrelated to treatment with Elevidys…Sarepta reported this event to FDA on June 18, 2025, via the FDA's postmarketing electronic database, FAERS. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies, and do so in accordance with applicable law and commitment to full regulatory transparency. Elevidys is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy.' Elevate Your Investing Strategy:
New York Post
7 hours ago
- New York Post
Breakthrough as two FDA-approved drugs are found to reverse Alzheimer's — including restoring memory
In a stunning scientific discovery, researchers have found that a pair of drugs can not only slow down Alzheimer's disease but actually reverse it and restore memory in mice. And the best part of all? Both are already FDA-approved — albeit for cancer. Researchers first pinpointed how Alzheimer's disease scrambles gene activity in individual brain cells. 3 Researchers have found that a pair of drugs can not only slow down Alzheimer's disease but actually reverse it and restore memory in mice. Pixel-Shot – Using the Connectivity Map database of 1,300 FDA‑approved drugs, the researchers looked for medications that reverse Alzheimer's‑associated gene expression — landing on a shortlist of five, and zeroing in on two cancer drugs. In what one researcher called a 'mock clinical trial,' they then mined 1.4 million patients' medical records, finding that those who had taken letrozole or irinotecan for cancer were significantly less likely to develop Alzheimer's. When given together in an aggressive Alzheimer's mouse model, letrozole — used to treat certain types of breast cancer in postmenopausal women — and irinotecan — an anti-cancer medication used to treat colon cancer and small cell lung cancer — reversed disease‑related gene expression signatures, dissolved toxic tau protein clumps and prevented brain degeneration. Most importantly, they restored memory and learning in mice that had already developed severe symptoms. It's an exciting development for an illness that's notoriously tricky. 3 Letrozole — used to treat certain types of breast cancer in postmenopausal women — and irinotecan — an anti-cancer medication used to treat colon cancer and small cell lung cancer — reversed disease‑related gene expression signatures, dissolved toxic tau protein clumps and prevented brain degeneration. Eric Hood – 'Alzheimer's disease comes with complex changes to the brain, which has made it tough to study and treat, but our computational tools opened up the possibility of tackling the complexity directly,' Marina Sirota, the interim director of the UCSF Bakar Computational Health Sciences Institute, said in a statement. 'We're excited that our computational approach led us to a potential combination therapy for Alzheimer's based on existing FDA-approved medications.' 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health,' said Yadong Huang, a professor of neurology and pathology at UCSF. 'This makes it very challenging for drug development — which traditionally produces one drug for a single gene or protein that drives disease.' 3 'Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health,' said Yadong Huang, a professor of neurology and pathology at UCSF. yurakrasil – The findings were published in the journal Cell. Both drugs are already FDA‑approved for other uses, which could dramatically speed up the path to human trials. However, because they are cancer drugs, repurposing them may be complex and risky. This finding adds to a growing number of potential Alzheimer's treatments. A compound found in rosemary and sage — carnosic acid — has been shown to reverse memory loss and reduce brain inflammation in mice with Alzheimer's, bringing their cognitive function back to near-normal levels. A study from Stanford Medicine found that seniors who received the shingles vaccine were 20% less likely to develop dementia over seven years. And researchers at Penn State and Stanford University discovered that a certain cancer drug could restore memory and brain function in early stage Alzheimer's models.
Wall Street Journal
8 hours ago
- Wall Street Journal
Vinay Prasad Is a Bernie Sanders Acolyte in MAHA Drag
Meet Vinay Prasad, a young disciple of Bernie Sanders who ranks as one of the most powerful officials in the federal government. He determines whether patients get access to many life-saving medicines. Or not. Think of him as a one-man death panel. Dr. Prasad was named by Marty Makary, the Food and Drug Administration commissioner, as head of the agency's biologics division in May, and last month as its chief medical and scientific officer. More on why he was tapped to these posts later. But it isn't an exaggeration to say that Dr. Prasad wields more power than Anthony Fauci ever did at the National Institutes of Health.
